Ironveld Plc (IRON)
LSE 
Summary
IRON Chart
Disc Medicine stock soars: take profit or buy into strength?
Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management said the APOLLO clinical trial met every primary and secondary endpoint, strengthening the firm's case for another FDA submission.
Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
Disc Medicine NASDAQ: IRON said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the company's plan to resubmit a new drug application to the U.S. Food and Drug Administration by the end of the year.
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.
Ironveld Plc (IRON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ironveld Plc ever had a stock split?
Ironveld Plc Profile
| Biotechnology Industry | Healthcare Sector | John D. Quisel CEO | LSE Exchange | G4947E100 CUSIP |
| US Country | 165 Employees | - Last Dividend | 30 Dec 2022 Last Split | 12 Aug 2020 IPO Date |
Overview
Disc Medicine, Inc., along with its subsidiaries, is a pioneering force in the biopharmaceutical realm, focusing its efforts on the clinical-stage development, discovery, and eventual commercialization of groundbreaking treatments aimed at tackling severe hematologic diseases within the United States. Established in 2017 and operating from its headquarters in Watertown, Massachusetts, Disc Medicine has strategically curated a robust portfolio consisting of both clinical-stage and preclinical product candidates. These candidates are specifically designed to target and modulate the fundamental biological pathways crucial to the formation and function of red blood cells, with a keen focus on heme biosynthesis and iron homeostasis, underscoring the company's commitment to addressing unmet needs in the field of hematologic health.
Products and Services
- Bitopertin: Aimed at treating a spectrum of erythropoietic porphyrias, including conditions such as erythropoietic protoporphyria and X-linked protoporphyria, as well as diamond-blackfan anemia. Bitopertin represents a novel approach in tackling these rare but debilitating diseases by potentially modifying the pathways associated with the production and function of red blood cells.
- DISC-0974: This candidate is tailored for patients suffering from anemia associated with myelofibrosis, as well as those grappling with anemia of chronic kidney disease. DISC-0974 exemplifies Disc Medicine's effort to combat these widespread conditions by targeting the underlying biological mechanisms, offering hope for improved patient outcomes in these areas.
- DISC-3405: Focused on the treatment of polycythemia vera and other related hematologic disorders, DISC-3405 aims to provide a solution for diseases characterized by an overproduction of red blood cells. Through its innovative design, DISC-3405 seeks to bring balance to red blood cell production and function, addressing a critical need in the management of these conditions.
- DISC-0998 (Preclinical): At the preclinical stage, DISC-0998 is being developed to address anemia associated with inflammatory diseases. This program highlights Disc Medicine's forward-thinking approach in expanding its portfolio to include treatments that cater to a broader range of hematologic disorders, especially those linked to inflammation, further solidifying its commitment to advancing hematologic health.
Contact Information
